Syntekabio Signs New Drug Development Agreement with Australian Medical Research Institute

AI drug development specialist Syntekabio announced on the 23rd that it has signed a Memorandum of Understanding (MOU) for joint research on new drug development and commercialization using its proprietary AI drug platform DeepMatcher® with QIMR Berghofer (QIMRB), a medical research institute in Australia.

QIMRB is a world-class medical research institute located in Brisbane, Australia. It conducts research on diseases in the fields of cancer, mental health and neuroscience, infection and inflammation, and population health through various methods including direct and collaborative research.

Following this MOU, Syntekabio will begin joint research with Professor Sudha Rao’s team at QIMRB on the development of anticancer therapeutics. Syntekabio will identify anticancer drug candidates using its AI platform DeepMatcher, and validate their efficacy using the efficacy platform of Professor Sudha Rao’s team.

Professor Sudha Rao was the first in Asia to establish a liquid biopsy clinical platform for non-invasive diagnosis of cancer patients’ blood samples. Using epigenetics-based markers, her main research area, she conducts various studies for immuno-oncology treatments and diagnostics.

Syntekabio and Professor Sudha Rao’s team have completed discussions on the joint research content and methods following the MOU, including exploring the development potential of anticancer targets proposed by QIMRB and sharing development strategies.

The candidate drugs derived from this project will have their intellectual property jointly secured by both parties. The technology will be licensed to global companies partnered with QIMRB to promote rapid commercialization.

Professor Sudha Rao stated, “By leveraging Syntekabio’s innovative AI drug development capabilities and the excellent research personnel at QIMR Berghofer Medical Research Institute, we expect to develop a new immunotherapy pipeline,” adding, “Through the rapid commercialization of the derived pipeline, we hope to help patients with metastatic solid tumors and chronic inflammatory diseases who have limited treatment options.”

Jongseon Jeong, CEO of Syntekabio, said, “Through joint research with QIMRB, we will build references for anticancer drug development and create an opportunity to secure technological competitiveness in the AI drug market,” and added, “We plan to expand cooperation with pharmaceutical and biotech companies for the development of therapeutics targeting various diseases.”